We support the adoption of stronger quality measures for HIV and viral hepatitis, including screening and treatment for hepatitis B and C, as well as a more accurate ADAP 340B calculation for the Medicare drug inflation rebate. Federal & state quality measures help ensure that health systems prioritize these key interventions.
We submitted comments on the 340B for Patients Act discussion draft, supporting legislative efforts to put the 340B Program on a firm statutory basis so that it can continue to serve people affected by HIV and other serious conditions far into the future. We urge Congress to protect HIV, STD, and other safety-net providers as well as ADAPs, and oppose provisions that would restrict subgrantee eligibility for STD clinics. We support an updated patient definition that does not restrict telemedicine or rapid start interventions. We also strongly support new transparency, reporting, and affordability requirements for hospitals, which account for the vast majority of 340B spending and growth but face no requirements to demonstrate patient benefit.
As a national patient advocacy organization that works to promote quality and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic conditions, we see firsthand how PBM practices, pharmacy access, and insurance design determine whether patients can remain on lifesaving treatment. We appreciate the Board’s continued focus on practical, patient-centered reforms that Oregon can move forward with.